X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs WYETH LTD - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD WYETH LTD BIOCON LTD/
WYETH LTD
 
P/E (TTM) x 92.6 27.7 334.0% View Chart
P/BV x 7.8 5.3 146.7% View Chart
Dividend Yield % 0.1 1.3 11.6%  

Financials

 BIOCON LTD   WYETH LTD
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
WYETH LTD
Mar-13
BIOCON LTD/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1,1881,044 113.7%   
Low Rs305818 37.3%   
Sales per share (Unadj.) Rs68.7298.6 23.0%  
Earnings per share (Unadj.) Rs7.657.2 13.2%  
Cash flow per share (Unadj.) Rs14.058.4 23.9%  
Dividends per share (Unadj.) Rs1.0017.00 5.9%  
Dividend yield (eoy) %0.11.8 7.3%  
Book value per share (Unadj.) Rs86.3249.5 34.6%  
Shares outstanding (eoy) m600.0022.72 2,640.8%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.93.1 348.3%   
Avg P/E ratio x98.916.3 607.6%  
P/CF ratio (eoy) x53.415.9 335.2%  
Price / Book Value ratio x8.63.7 231.6%  
Dividend payout %13.229.7 44.6%   
Avg Mkt Cap Rs m447,90021,157 2,117.0%   
No. of employees `0006.10.5 1,249.8%   
Total wages/salary Rs m9,311400 2,327.8%   
Avg. sales/employee Rs Th6,705.813,787.4 48.6%   
Avg. wages/employee Rs Th1,514.2813.0 186.3%   
Avg. net profit/employee Rs Th736.92,643.3 27.9%   
INCOME DATA
Net Sales Rs m41,2346,783 607.9%  
Other income Rs m2,062353 584.8%   
Total revenues Rs m43,2967,136 606.7%   
Gross profit Rs m8,2911,617 512.6%  
Depreciation Rs m3,85127 14,477.4%   
Interest Rs m6156 11,181.8%   
Profit before tax Rs m5,8871,938 303.8%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m1,569632 248.2%   
Profit after tax Rs m4,5311,301 348.4%  
Gross profit margin %20.123.8 84.3%  
Effective tax rate %26.732.6 81.7%   
Net profit margin %11.019.2 57.3%  
BALANCE SHEET DATA
Current assets Rs m41,4866,984 594.0%   
Current liabilities Rs m21,4132,056 1,041.5%   
Net working cap to sales %48.772.6 67.0%  
Current ratio x1.93.4 57.0%  
Inventory Days Days6499 64.4%  
Debtors Days Days9424 393.4%  
Net fixed assets Rs m50,661244 20,737.2%   
Share capital Rs m3,000227 1,320.4%   
"Free" reserves Rs m48,8085,441 897.1%   
Net worth Rs m51,8085,668 914.0%   
Long term debt Rs m17,89825 71,592.0%   
Total assets Rs m99,8977,901 1,264.4%  
Interest coverage x10.6353.3 3.0%   
Debt to equity ratio x0.30 7,832.4%  
Sales to assets ratio x0.40.9 48.1%   
Return on assets %5.216.5 31.2%  
Return on equity %8.722.9 38.1%  
Return on capital %9.634.0 28.3%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m12,05815 79,328.9%   
Fx outflow Rs m7,3482,677 274.5%   
Net fx Rs m4,710-2,662 -176.9%   
CASH FLOW
From Operations Rs m6,621923 717.2%  
From Investments Rs m-6,840317 -2,158.4%  
From Financial Activity Rs m-2,397-481 498.3%  
Net Cashflow Rs m-2,612759 -344.1%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 51.1 40.3%  
Indian inst/Mut Fund % 8.4 11.3 74.3%  
FIIs % 10.7 7.2 148.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 30.4 65.5%  
Shareholders   109,995 21,978 500.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (4QFY18); Net Profit Up 19.8% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 19.8% YoY). Sales on the other hand came in at Rs 12 bn (up 25.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 18, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - SHASUN PHARMA COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS